CERE News and Press, Ceres Inc. From 06/15/22

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of di...

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in...

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2022 Earnings Conference Call May 10, 2022 08:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Ray Sanchez - Chief Medical Officer John R...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q1 - Results - Earnings Call Presentation

Cerevel Therapeutics press release (NASDAQ:CERE): Q1 GAAP EPS of -$0.46. Cash, cash equivalents and marketable securities of $550.9M are expected to continue to support operations into 2024. “Cerevel remains in an enviable position of strength as we seek to transform what is possi...

On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents...

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2...

Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy Poster presentations to include further evidence of tavapadon’s consistent pharmacokinetic and pharmacodynamic profile CAMBRIDG...

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles, M.D. will participate...

Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Matthew Calistri - Vice President of Investor Relations Tony Coles - Chairperson & Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scie...